The U.S. energy renaissance has been one of the bright spots in American industry, and its success has also brought an unforeseen boom in manufacturing. Much of the recent boom has been from unconventional sources such as shale, a resource that wasn’t even mentioned in the Energy Information Administration’s Energy Outlook Report 10 years ago. Today, it accounts for more than 30% of total natural gas production in the United States.
We aren’t the only ones with reserves, but we harnessed these unconventional sources effectively and economically, and we did it faster than any other country. According to a panel of experts at the 2013 Energy Forward Conference, only China will be able to effectively match the U.S. in terms of shale gas production for 10 to 15 years.
Let’s take a look at a few reasons we won the shale gas race.
Regulations and governmental structure
Unlike many other countries around the world, the U.S. has a robust system that protects individual property and patents. According to a Wells Fargo panelist at the 2013 Energy Forward Conference, the U.S. is one of the few countries in the world where an individual landowner has mineral rights for anything found on his or her property, and contract rights can be structured for extraction from that individual landowner.
Top 5 Oil Service Stocks To Own Right Now: Shutterfly Inc.(SFLY)
Shutterfly, Inc. provides an Internet-based social expression and personal publishing service that enables consumers to share, print, and preserve their digital photos through the medium of photography in the United States. It offers a range of personalized photo-based products and services for consumers to upload, edit, enhance, organize, find, share, create, print, and preserve their memories. The company produces and sells photo books, greeting and stationery cards, personalized calendars, and other photo-based merchandise, including calendars, mugs, canvas prints, mouse pads, magnets, and puzzles. It also offers photo prints consist of wallet and photocards. In addition, the company provides commercial print services. Shutterfly, Inc. was founded in 1999 and is headquartered in Redwood City, California.
- [By John Kell]
Shutterfly Inc.’s(SFLY) fourth-quarter earnings fell 18% as the e-commerce company recorded higher expenses. Shutterfly also said it expects to post a loss for the current year. Shares dropped 7.6% to $45.90 premarket.
- [By Rich Smith]
Redwood City, Calif.-based Shutterfly (NASDAQ: SFLY ) has acquired photo bookmaking software producer MyPublisher.
Calling its new acquisition’s software client “best in class,” Shutterfly CEO Jeffrey Housenbold argued that in conjunction with Shutterfly’s own cloud-based platform, the companies are ready to “set the standard for design, choice and quality in the personal publishing and social expression category.”
Top 5 Oil Service Stocks To Own Right Now: Rite Aid Corp (RAD)
Rite Aid Corporation, incorporated in 1968, is a retail drugstore chain in the United States. As of March 3, 2012, the Company operated drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,667 stores. In the Company’s stores, it sells prescription drugs and a range of other merchandise, which it calls front end products. During the fiscal year ended March 3, 2012 (fiscal 2012), prescription drug sales accounted for 68.1% of its total sales. The Company carries a range of front end products, which accounted for 31.9% of its total sales in fiscal 2012. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise and other everyday and convenience products, as well as photo processing. It offers a variety of products under its private brands, which contributed approximately 17% of it s front end sales in the categories where private brand products were offered in fiscal 2012. As of March 3, 2012, the Company had opened over 2,100 GNC stores-within-Rite Aid-stores. During fiscal 2012, the Company sold two owned operating stores to independent third parties.
During fiscal 2012, its stores filled approximately 295 million prescriptions and served an average of 2.1 million customers per day. The overall average size of each store in its chain is approximately 12,600 square feet. As of March 3, 2012, 60% of its stores were freestanding; 51% of its stores included a drive-thru pharmacy; 24% included one-hour photo shops, and 46% included a GNC store-within-Rite Aid-store. The Company’s customers may also order prescription refills over the Internet through www.riteaid.com, or over the phone through its telephonic automated refill systems for pick up at a Rite Aid store. It has a strategic alliance with GNC, a retailer of vitamin and mineral supp lements.
- [By Laura Brodbeck]
Next week investors will be waiting for several key earnings reports including JP Morgan Chase & Co. (NYSE: JPM), Alcoa Inc. (NYSE: AA), Rite Aid Corporation (NYSE: RAD) and Family Dollar Stores (NYSE: FDO).
- [By Jon C. Ogg]
Rite Aid Corporation (NYSE: RAD) is a turnaround which keeps on turning. That is the theory from Goldman Sachs at least. The brokerage firm upgraded shares of the retail drug store to Buy from Neutral. Perhaps more important is that the price target was raised to $8 from $5 in the call.
- [By Grace L. Williams]
Shares of CVS have advanced 2.7% to $68.74 at 3:0 p.m., trailing Walgreen’s (WAG) 5.3% rise to $63.87 but besting Rite Aid’s (RAD) 1.5% gain to $5.72.
- [By Reuters]
Julio Cortez/AP NEW YORK — Many U.S. retailers had to ramp up promotions last month as shoppers continued to watch their spending during the holiday season, hitting profits at several chains. L Brands (LB) cut its earnings forecast for the holiday quarter Thursday after reporting disappointing December sales at its Victoria Secret and La Senza chains. The company said it had to offer more deals than expected, the second month in a row it has had to do so. Family Dollar Stores (FDO) and teen retailer Zumiez (ZUMZ), which both reported sales declines for December, also slashed their profit forecasts. Even retailers that saw big sales gains, such as Kay Jewelers parent Signet Jewelers (SIG), weren’t spared. “Additional discounting was necessary in a highly promotional retail environment,” Signet Chief Executive Officer Mike Barnes said in a statement. A group of nine U.S. retailers in the Thomson Reuters same-store sales index are expected Thursday to report a sales rise of 1.9 percent in December at stores open at least a year, well below the 7.2 percent increase of a year earlier. Including drugstore chains Walgreen (WAG) and Rite Aid (RAD), analysts estimate the rise at 2.7 percent. Gap (GPS) will report after the markets close Thursday. Faced with reticent shoppers worried about their job prospects and modest economic growth, retailers offered more discounts during the holiday season than a year earlier. Between Nov. 3 and Jan. 4, eight retailers, including Walmart Stores (WMT), Target (T) and Macy’s (M) , increased the number of circulars published by 6 percent and sent 57 percent more promotional emails, according to data prepared for Reuters by MarketTrack. Retailers also had to deal with shoppers who were less willing to go into stores: Data firm ShopperTrak this week said foot traffic had dropped 14.6 percent this holiday season. Walgreen, whose comparable sales of general merchandise rose 2.5 percent in December, said fewer shoppers had com
Top 5 Oil Service Stocks To Own Right Now: Seattle Genetics Inc.(SGEN)
Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
- [By Rich Bieglmeier]
[Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]
Let’s take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.
- [By Sean Williams]
These might not be household names in the U.S., but they do brandish global licensing partnerships with companies that might be more familiar to you. Takeda, for example, has licensing agreements in place with Orexigen Therapeutics (NASDAQ: OREX ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN ) with regard to FDA-approved Hodgkin lymphoma drug Adcetris.
- [By Roberto Pedone]
One biotechnology player that insiders are snapping up a huge amount of stock in here is Seattle Genetics (SGEN), which develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Insiders are buying this stock into huge strength, since shares are up sharply by 72% so far in 2013.
Seattle Genetics has a market cap of $4.9 billion and an enterprise value of $4.5 billion. This stock trades at a premium valuation, with a price-to-sales of 19.09 and a price-to-book of 21.65. Its estimated growth rate for this year is -37%, and for next year it’s pegged at -6.3%. This is a cash-rich company, since the total cash position on its balance sheet is $373.85 million and its total debt is zero.
A director just bought 1,005,901 shares, or about $43.44 million worth of stock, at $42.31 to $43.98 per share.
From a technical perspective, SGEN is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares dropping from its high of $45.37 to its intraday low of $39.85 a share. During that move, shares of SGEN have been consistently making lower highs and lower lows, which is bearish technical price action.
If you’re bullish on SGEN, then I would look for long-biased trades as long as this stock is trending above its 200-day of $38.40 or above more near-term support at $36.79 and then once it takes out its 50-day at $41.02 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 856,995 shares. If we get that move soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $45.37 $46.48 a share. Any high-volume move above those levels will then give SGEN a chance to tag its 52-week high at $49.23 a share.
- [By Brian Orelli]
It’s certainly in the FDA’s right to ask outside experts for their opinion; I would argue it’s not all that surprising even if the FDA is leaning strongly toward approving the drug. There are plenty of cases — Seattle Genetics’ (NASDAQ: SGEN ) Adcetris, for example — where the FDA called a meeting only to gush all over the drug. The drug got a unanimous positive recommendation from the panel and was approved early by the FDA.
Top 5 Oil Service Stocks To Own Right Now: Netflix Inc.(NFLX)
Netflix, Inc. provides Internet subscription services for TV shows and movies in the United States and internationally. The company offers its subscribers to watch unlimited TV shows and movies streamed over the Internet to their TVs, computers, and mobile devices. It also provides standard definition DVDs and Blu-ray discs to its subscribers. The company was founded in 1997 and is headquartered in Los Gatos, California.
- [By Sue Chang and Saumya Vaishampayan]
Facebook Inc. (FB) shares fell 4.6% while Tesla (TSLA) shed 5.9%, its worst percentage drop so far this year. Both stocks have now fallen more than 20% from their recent highs. Netflix Inc. (NFLX) also slid 4.9% while Priceline Group Inc. (PCLN) dropped 4.8%.
- [By Jonathan Berr]
Technological Prowess: Apple’s stock has skyrocketed in recent years thanks to revolutionary product (iPod, iPhone and iPad) after revolutionary product — but also on their many iterations. Next up for the company is likely the iPhone 6, which according to MacRumors is expected to launch Apple into the big-screen phone arena (something many Apple fans have yearned for), and should utilize a faster chip than current models. However, AAPL also reportedly is in talks with Comcast (CMCSA) about developing a video streaming/cable alternative that would presumably take on Netflix (NFLX); working on developing specialized applications for cars known as telematics; and has brought streaming capability to iTunes to further assert its musical dominance.Reports that the company’s best days are behind it seem harsh.
- [By Matthew Argersinger and Eric Bleeker, CFA]
Yet, as Eric notes, it’s also a space where ad rates could be far more erratic than long-established norms on television. That makes basing business decisions on today’s video rates riskier, especially relative to the consistency of a plan like Netflix’s (Nasdaq: NFLX), which sets a stable recurring monthly revenue stream.
- [By Charley Blaine]
Netflix Inc. (NASDAQ: NFLX) fell $6.84, or 1.9%, to $352.03. For the month, the shares stumbled 21%; they dropped 4.4% for the quarter. Amazon.com Inc. (NASDAQ: AMZN) closed down 0.5% to 336.52. It fell 6.1% for the month and 15.6% for the quarter. Google Inc. (NASDAQ: GOOG) fell 8.3% for the month and 0.6% for the quarter. It at least ended the month as the world’s thirst most valuable company. Staples (Nasdaq: SPLS) has no similar silver lining for its lackluster performance.
Top 5 Oil Service Stocks To Own Right Now: Entegris Inc. (ENTG)
Entegris, Inc. develops, manufactures, and supplies products and materials used in processing and manufacturing in the semiconductor and other high-technology industries worldwide. It operates in three segments: Contamination Control Solutions, Microenvironments, and Specialty Materials. The Contamination Control Solutions segment offers liquid filtration products, components and systems, and gas filtration products that purify, monitor, and deliver critical liquids and gases to the semiconductor manufacturing process and similar manufacturing processes. The Microenvironments segment provides wafer and reticle handling products, wafer shipping products, and data storage products to preserve the integrity of wafers, reticles, and electronic components at various stages of transport, processing, and storage. The Specialty Materials segment offers graphite components used in semiconductor equipment; and low-temperature, plasma-enhanced chemical vapor deposition coatings for c ritical components of semiconductor manufacturing equipment used in various stages of the manufacturing process. The company sells its products primarily through direct sales force, and strategic and independent distributors to integrated circuit device manufacturers, original equipment manufacturers (OEM), gas and chemical manufacturing companies, and high-precision electronics manufacturers; and electrical discharge machining customers, glass container manufacturers, aerospace manufacturers, and biomedical implantation device manufacturers, as well as flat panel display OEMs, materials suppliers, and end users. Entegris, Inc. was founded in 1966 and is headquartered in Billerica, Massachusetts.
- [By Vanina Egea]
ATMI supplies high performance materials, materials packaging and materials delivery systems for use in the manufacture of microelectronics devices worldwide. ATMI agreed to be acquired by Entegris (ENTG) for $1.15 billion, or $34 per share. The deal will provide a lot more of product offerings. The acquisition is expected to close during the second calendar quarter of 2014.
- [By Jake L’Ecuyer]
Equities Trading UP
ATMI (NASDAQ: ATMI) shot up 25.51 percent to $33.80 after the company reported upbeat Q4 earnings. Entegris (NASDAQ: ENTG) announced its plans to acquire ATMI.
- [By Michael Calia]
Entegris Inc.(ENTG) agreed to acquire ATMI for $1.15 billion, a deal that would combine two semiconductor industry suppliers in Entegris’ bid to become a more global leader. Entegris shares surged 17% to $12 premarket, while ATMI rose 25% to $33.76, approaching the offer price of $34 a share.
- [By Ben Axler]
In the table below, we’ve listed a sample of small-cap semiconductor capital equipment stocks such as Entegris (ENTG), Advanced Energy Industries (AEIS), ATMI Inc. (ATMI), MKS Instruments (MKSI), Photronics Inc. (PLAB), Rudolph Technologies (RTEC),FormFactor (FORM) and Mattson Technology (MTSN). The peers trade at approximately 1.0x and 15.5x 2014E revenues and EPS, respectively. Furthermore, the average peer trades at 2.1x tangible book value. However, these multiples are based on average 2014E industry revenue and earnings growth of 18% and 119%, respectively. Axcelis is poised to grow at a rate substantially above the industry average.